Science

Covid vaccine: Bharat Biotech’s Covaxin shows ‘robust’ results in phase-1 trials

Our Bureau Hyderabad | Updated on December 17, 2020

Bharat Biotech’s Covid-19 vaccine candidate, Covaxin, has shown `robus’ results in Phase I trials, says a study shared on a public platform before peer review.

According to the research paper, ‘A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine’, the results have been ‘promising’.

“Reactogenicity was absent in the majority of participants, with mild events. The majority of adverse events were mild and were resolved. One serious adverse event was found to be unrelated to vaccination,’’ the paper said.

Also read: 64 envoys visit Bharat Biotech, Biological Evans facilities

All three vaccine formulations resulted in robust immune responses comparable to a panel of convalescent serum, the study said.

The vaccine candidate induced binding and neutralising antibody responses, it added.

Covaxin is now undergoing Phase-III trials. It is India’s first indigenous Covid-19 vaccine being developed by Hyderabad-based Bharat Biotech in association with Indian Council of Medical research.

Published on December 17, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like